A Sustainable Biologic Solution Gains Major Insurance Coverage and Proves Superior to Synthetic Alternatives in Real-World Clinical Data

In the world of advanced wound care and reconstructive surgery, an unlikely material is sparking what can only be described as a quiet revolution. As reported on Kerecis, fish skin—sustainably sourced, gently processed, and naturally structured—is rapidly becoming the go-to choice for treating severe burns and chronic wounds across American hospitals. Major insurance companies, Medicare, and state Medicaid programs are now covering the treatment, representing a significant shift in how American healthcare approaches wound healing.

A Material That Mimics Nature

At first glance, the idea of using fish skin to heal human wounds might seem unconventional. But the science behind it is elegant. Unlike heavily processed synthetic materials or reconstituted collagen products, intact fish-skin grafts preserve the natural three-dimensional structure of biological tissue. This structural integrity matters enormously for wound healing.

“When grafted onto damaged human tissue, the patented material supports the body’s own processes to heal and regenerate,” according to Kerecis, the company pioneering this approach. Because there is no viral or prion transfer risk between Atlantic cod and humans, the fish skin can be processed gently—preserving its natural strength, complexity, and biochemical components including fatty acids—rather than being heavily modified into something synthetic.

The result: a biologic material that works with the body’s natural healing mechanisms rather than against them.

The Insurance Coverage Breakthrough

For years, innovative medical treatments have faced a common barrier: insurance coverage. No matter how effective a new therapy might be, if insurance companies won’t pay for it, patients struggle to access it and hospitals hesitate to adopt it.

That dynamic has shifted dramatically for fish-skin grafts. In August 2026, Kerecis announced a massive expansion in insurance coverage, adding more than 40 million covered lives through policy updates across multiple large national and regional insurers, as well as state Medicaid programs. The company is now included in policy frameworks formed by the Blue Cross Blue Shield Association, representing more than 30 independent health plans.

This expansion reflects a broader trend in healthcare decision-making. “We are seeing a clear shift in how payors evaluate biologic solutions,” said Fertram Sigurjonsson, Founder and CEO of Kerecis. “Coverage decisions are increasingly grounded in clinical outcomes, practical applicability, and the ability to reduce downstream burden on the healthcare system. That is where fish skin grafts are resonating.”

The insurance industry’s embrace of fish-skin grafts represents validation from the financial gatekeepers of American healthcare. These are not decisions made lightly. As Sigurjonsson notes, “Coverage determines whether innovation is actually used. What we are seeing now is access catching up with clinical experience. That is when adoption accelerates.”

The Clinical Evidence: Real-World Results Across 61 Burn Centers

While insurance coverage reflects confidence, it’s ultimately clinical data that drives adoption. A new study analyzing outcomes across 61 U.S. burn centers provides compelling evidence of fish-skin grafts’ superiority over conventional alternatives.

The study, drawing on data from the American Burn Association’s Burn Care Quality Platform database, compared outcomes for 465 severely burned patients. Some received intact fish-skin grafts from Kerecis, while others received treatments made from reconstituted cross-linked collagen and synthetic polyurethane—materials that do not replicate the structure of native human tissue.

The results were striking:

Hospital Length of Stay: Patients treated with intact fish-skin grafts spent significantly less time hospitalized: 24.2 days versus 33.5 days for those receiving synthetic alternatives. For severely burned patients, reducing hospital stay by more than a week represents not just clinical improvement but substantial reduction in healthcare costs and patient suffering.

Graft Failure: Perhaps most importantly, graft loss—when the grafted skin fails to take—occurred in only 3.2% of patients treated with fish skin versus 8.3% of those receiving synthetic materials. Graft failure is a serious complication that can necessitate repeated procedures and prolonged hospitalization.

Additional Complications: The study also found that sepsis (life-threatening infection), venous thromboembolism (blood clots), and hospital-acquired pressure injuries were all numerically lower in the intact fish-skin group.

As Sigurjonsson summarizes: “The real-world comparative data shows that hospital stays are shorter for burn patients treated with intact fish-skin grafts than for those treated with products that do not replicate the structure of native human tissue.”

Why Structure Matters

Understanding why fish-skin grafts outperform synthetic alternatives requires appreciating a fundamental principle of tissue engineering: structure matters. The three-dimensional architecture of tissue isn’t merely decorative—it’s functional. It provides scaffolding for cells to migrate, differentiate, and regenerate.

Synthetic materials and heavily processed biological products lose much of this structural complexity. Fish skin, by contrast, retains its natural organization. “Unlike heavily processed or synthetic materials, fish skin maintains structural and biochemical components that enable efficient wound bed preparation and reliable progression toward closure,” according to information from Kerecis.

This preservation of natural structure explains why fish-skin grafts support cellular ingrowth and tissue regeneration more effectively than alternatives. The body recognizes the material as similar to human tissue and responds accordingly, facilitating integration rather than rejection.

Beyond Burns: Diabetic Foot Ulcers and Beyond

While the recent study focused on severe burns, fish-skin grafts are making an impact across wound care. “In addition to burns, Kerecis ranks in the top two widest covered skin substitutes for diabetic foot ulcers”—one of the most challenging chronic wound problems facing American medicine.

Diabetic foot ulcers affect millions of Americans and are a leading cause of non-traumatic lower-limb amputations. The ability to accelerate healing and improve outcomes in this population represents genuine progress against a source of significant disability.

Sustainability: Medicine Meets Environmental Responsibility

There’s an additional dimension to fish-skin grafts’ appeal: sustainability. Kerecis sources its material from Icelandic Atlantic cod and processes it using renewable energy, aligned with the United Nations Sustainable Development Goals.

This approach addresses a growing concern in healthcare: the environmental footprint of medical innovation. By utilizing sustainably sourced biological material rather than relying on energy-intensive synthetic alternatives, fish-skin grafts offer both superior clinical performance and environmental responsibility.

A Paradigm Shift in Advanced Wound Care

The convergence of clinical evidence, insurance coverage expansion, and real-world adoption across dozens of burn centers represents something significant: a paradigm shift in how American healthcare approaches wound healing. For decades, synthetic materials dominated because they offered consistency and ease of manufacture. But as clinical data accumulated showing superior outcomes with biologic materials that preserve tissue structure, the field began to shift.

Fish-skin grafts represent the intersection of multiple trends: evidence-based medicine, biologic innovation, and practical cost-effectiveness. Insurance companies cover them because they work better and reduce overall healthcare costs. Hospitals adopt them because they improve patient outcomes and reduce complications. Patients benefit because they experience faster healing and better functional results.

“Securing these policy inclusions is a direct reflection of our targeted clinical trial strategy and the undeniable biological advantages of intact fish skin,” said Gunnar Johannsson, MD, Senior Vice President and Medical Director at Kerecis. “Major payors demand definitive evidence that a biologic solution reliably advances tissue regeneration. Our data establishing efficacy in the most severe ulcers sets a new clinical benchmark, and that clear differentiation is driving these coverage decisions.”

What This Means for Patients

For the thousands of Americans hospitalized with severe burns each year, and for millions living with chronic wounds like diabetic foot ulcers, this represents genuine progress. Fish-skin grafts offer:

• Faster healing supported by biological structure that mimics human tissue
• Reduced complications including lower rates of infection and graft failure
• Shorter hospital stays reducing both costs and patient suffering
• Broader access through expanded insurance coverage
• Proven clinical superiority validated by real-world data across multiple institutions

For patients facing the physical and emotional burden of severe wounds or burns, access to a treatment that demonstrably accelerates healing and improves outcomes is genuinely life-changing.

The Bigger Picture

The rise of fish-skin grafts in American medicine illustrates an important principle: innovation doesn’t always mean high-tech complexity. Sometimes it means returning to natural materials, understanding why they work, and processing them in ways that preserve their inherent advantages.

A sustainably sourced material from the Atlantic, gently processed in Iceland, is now healing America’s most severe wounds more effectively than synthetic alternatives. That’s not just a medical breakthrough—it’s a model for how modern healthcare can combine biological sophistication with environmental responsibility.

As fish-skin grafts continue their quiet revolution in American hospitals, they’re proving that the most effective solutions sometimes come not from laboratories, but from nature itself.